针对关节疾病相关蛋白的自身抗体作为诊断类风湿关节炎的新型生物标志物
本研究开发并表征了一种多重免疫分析法,用于检测针对关节中表达的疾病相关蛋白肽段的自身抗体。在3个独立类风湿关节炎队列(n=2110)及骨关节炎、银屑病关节炎、系统性红斑狼疮患者中验证,该法对早期血清阴性类风湿关节炎具有高鉴别能力。
要点
- 5种肽抗原以99%特异性(95%CI 98-100%)区分类风湿关节炎患者与健康对照。
- 新型生物标志物可识别22.5%(95%CI 19-26%)抗CCP抗体和类风湿因子均阴性的早期类风湿关节炎患者。
- 该免疫分析法对早期血清阴性类风湿关节炎具有高鉴别能力。
核心结论
- 基于关节疾病相关蛋白肽段的多重免疫分析法可用于检测类风湿关节炎血清中的特异性自身抗体。
- 该免疫分析法对早期血清阴性类风湿关节炎具有高鉴别能力。
研究设计与样本
- 基于小鼠模型中选择的关节表达蛋白的人源对应肽段,采用基于珠子的流式免疫分析法检测IgG抗体,选择含表位的三螺旋或环状肽以避免共线性反应。
- 在3个独立类风湿关节炎队列(n=2110)、瑞典年龄和性别匹配的健康对照以及骨关节炎、银屑病关节炎和系统性红斑狼疮患者中验证该免疫分析法。
主要发现
- 筛选试验显示5种肽抗原以99%特异性(95%CI 98-100%)区分类风湿关节炎患者与健康对照。
- 在验证研究中,于另外2个类风湿关节炎队列中重现了自身抗体的鉴别能力,显示其对类风湿关节炎与骨关节炎、银屑病关节炎和系统性红斑狼疮具有高鉴别能力。
- 新型生物标志物识别了22.5%(95%CI 19-26%)抗环瓜氨酸肽抗体和类风湿因子均阴性的早期类风湿关节炎患者。
- 使用2个独立类风湿关节炎患者队列及骨关节炎、银屑病关节炎和系统性红斑狼疮患者队列的验证研究确认了该生物标志物在识别血清阴性类风湿关节炎患者中的实用性。
关键数值与推荐
- 5种肽抗原区分类风湿关节炎患者与健康对照的特异性为99%(95%CI 98-100%)。
- 新型生物标志物识别22.5%(95%CI 19-26%)抗环瓜氨酸肽抗体和类风湿因子均阴性的早期类风湿关节炎患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study was undertaken to develop and characterize a multiplex immunoassay for detection of autoantibodies against peptides derived from proteins known to play a role in development of arthritis and that are also expressed in joints. METHODS: We selected peptides from the human counterpart of proteins expressed in the joints, based on mouse models that showed these to be targeted by pathogenic or regulatory antibodies in vivo. Using bead-based flow immunoassays measuring IgG antibodies, we selected triple helical or cyclic peptides, containing the epitopes, to avoid collinear reactivity. We characterized the analytical performance of the immunoassay and then validated it in 3 independent rheumatoid arthritis (RA) cohorts (n = 2,110), Swedish age- and sex-matched healthy controls, and patients with osteoarthritis (OA), patients with psoriatic arthritis (PsA), and patients with systemic lupus erythematosus (SLE). RESULTS: Screening assays showed 5 peptide antigens that discriminated RA patients from healthy controls with 99% specificity (95% confidence interval [CI] 98-100%). In our validation studies, we reproduced the discriminatory capacity of the autoantibodies in 2 other RA cohorts, showing that the autoantibodies had high discriminatory capacity for RA versus OA, PsA, and SLE. The novel biomarkers identified 22.5% (95% CI 19-26%) of early RA patients seronegative for anti-cyclic citrullinated peptide and rheumatoid factor. The usefulness of the biomarkers in identifying seronegative RA patients was confirmed in validation studies using 2 independent cohorts of RA patients and cohorts of patients with OA, PsA, and SLE. CONCLUSION: A multiplex immunoassay with peptides from disease-related proteins in joints was found to be useful for detection of specific autoantibodies in RA serum. Of note, this immunoassay had high discriminatory capacity for early seronegative RA.
引用
- Lönnblom E, Leu Agelii M, Sareila O, et al. Autoantibodies to Disease-Related Proteins in Joints as Novel Biomarkers for the Diagnosis of Rheumatoid Arthritis. Arthritis Rheumatol. 2023. PMID: 36718635. doi:10.1002/art.42463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。